

January 7, 1969

Dr. Thomas V. Kalcher  
Geigy Pharmaceuticals  
Ardsley, New York 10502

Dear Dr. Kalcher:

Enclosed is a definitive protocol for the study of GP 41299. We would propose a step-wise approximation to the clinical evaluation of this compound.

If the program for the initial EEG trials are satisfactory, we will file the protocol with our Committees. In such straight-forward studies, approval is generally available within 4 weeks. This will provide an opportunity for us to select subjects and to file the necessary forms for the FDA.

If this protocol is acceptable, we will require 50 capsules of 25 mg GP 41299 and, if possible, 25 capsules of an inactive placebo, as lactose or dextrose.

Thank you for the opportunity of preparing this protocol.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp